TGFB1 and nosocomial infection: Although the molecular mechanism of TGF-β1 inhibition by astragaloside IV remains unknown, findings of this study revealed the protective effects of astragaloside IV in a K. pneumoniae model, which is of great importance to provide clues for treatment of this hospital-acquired infection.